Pulmonary arterial hypertension (PAH), a fatal disease of unknown etiology characterized by
impaired regulation of pulmonary hemodynamics and vascular growth, is associated with …

Pulmonary arterial hypertension (PAH) is an insidious disease of the small pulmonary
arteries that is progressive in nature and results in right heart strain/hypertrophy and …

Vascular remodeling and smooth muscle cell proliferation are hallmark pathogenic features
of pulmonary artery hypertension (PAH). Alterations in the metabolism of l-arginine via …

Activated arginase has been implicated in many diseases including cancer, immune cell
dysfunction, infections, and vascular disease. Enhanced arginase activity has been reported …

Background Endothelial dysfunction may contribute to the pathogenesis of pulmonary
hypertension through impaired production of the endothelium-derived vasodilator nitric …

Background—Pulmonary arterial hypertension is a progressive proliferative vasculopathy of
the small pulmonary arteries that is characterized by a primary failure of the endothelial nitric …

Background Pulmonary hypertension is characterized by abnormal thickening of the
pulmonary arteries and increased pulmonary vascular resistance. Nitric oxide is a potent …

Secondary pulmonary hypertension (PH) is emerging as one of the leading causes of
mortality and morbidity in patients with hemolytic anemias such as sickle cell disease (SCD) …

Nitric oxide (NO) is produced by NO synthase (NOS) from l-arginine (l-Arg). Alternatively, l-
Arg can be metabolized by arginase to produce l-ornithine and urea. Arginase (AR) exists in …

Endothelial cells (EC) metabolize l-arginine mainly by arginase, which exists as two distinct
isoforms, arginase I and II. To understand the roles of arginase isoforms in EC arginine …